The deal will significantly increase the scale of production of both Caumz (synthetic tetrahydrocannabinol (THC) and cannabidiol (CBD)) and HCC011 (inhaled delta-9-THC) – with production capacity increased from 2,500 dosing capsules in a three-day period to 100,000 dosage units in a single eight-hour period.
In addition, the products will receive four additional manufacturing patents related to the production method.
The partnership sees Vitiprints, a specialist in 2D printing technology, provide Tetra Bio-Pharma with an exclusive license to use the technology for the commercial production of its two drug candidates, for use within a vaporizing system, Caumz-kit.
In exchange for the license to use the technology, Vitiprints will receive undisclosed milestone and royalty payments based on potential sales of the Caumz product.
Vitiprints will visit Tetra’s manufacturing site in Moncton, Canada, with the aim of introducing its technology to the site during the spring of this year, the company stated.
Guy Chamberland, Tetra’s CEO, noted that once this has been implemented, a further scale-up and transfer will take place in its Greater Montreal facility.
The company added that this method of manufacture will reduce cost of goods sold by 75%.
Caumz is currently at the Phase II trial stage for the treatment of both advanced cancer pain and breakthrough pain, while HCC011 is being investigated at the same stage for hepatocellular carcinoma.
In the latter indication, Tetra is exploring HCC011 to improve quality of life for cancer patients, as well as exploring potential antitumor activity.
Based on consultation with the US Food and Drug Administration (FDA), Tetra will apply for approval through fast track designation and accelerated approval for Caumz.